Aims:Germ cell tumors (GCT) are uncommon in children and adolescent but when they appear, gonads are the most frequent site. Testicular tumors constitute 1-2% of all pediatric solid tumors among them 84% are GCT. Incidence of ovarian GCT is 67%. This study from a single center focus on highlighting clinical features, investigations, treatment and outcome of GCTs in children to look for peri operative challenges and long term prognosis.MethodsA prospective study of 45 patients with GCTs was done from March 2018 to January 2022. The detailed data of each patient was scrutinized including history, physical examination, investigations, management, and follow-up. Forty-five patients presented during this period. Fifteen male (33.3%) and 30(66.7%) female with median age of 4.8 years. Twenty-eight( 62.2%) patients presented with abdominal mass, 15(34.88%) with scrotal swelling and 2(4.65%) with acute abdomen. Hematological and radiological investigations were done in all patients. α-fetoprotein level was high in 30 patients. All patients were managed combinedly with Paediatric Oncology. After being discussed in multidisciplinary tumor board, surgical excision was done.Results:On gross, 75% were mixed and 25% were solid tumors. Median size of testicular tumors ranged from 3cm to 8cm while ovarian tumors ranged from 5cm to 23cm. on histology, Twenty six(57.8%) were mature teratoma, 6 (15.5%) immature teratoma, 8(17.7%) yolk sac tumors, while 1(2.32%) mixed stromal tumor, 1 (2.32%) sex cord tumor and 1(2.2%) Leydig cell tumor also reported. Neo-adjuvant chemo was given in 4 (8.88%) patients while 6 (13.33%) patients received chemotherapy postoperatively. Rest of the patients didnot receive chemotherapy as they had stage I & II disease. Thirty-three patients are doing fine, 11 had lost follow up and 1 patient expired due to sepsis. Long term follow-up with tumor markers and radiological investigations showed no recurrence in majority of patients (73%).ConclusionGCTs in Pediatric population are not uncommon. However good prognosis can be expected if diagnosed at early stage. Majority of tumors doesn’t require post-operative chemotherapy. Tumor markers especially alpha-fetoprotein seems reasonable prognostic marker on follow up in centers where other genetic studies aren’t available due to limited resources.
The antifeedants Brestan, Brestanol, Duter, Duter tetra and Suzo were investigated against the greasy cutworm, Agrotis ypsilon Rott. Seven concentrations of each material were prepared in water i.e. 10 000, 5000, 1000, 800, 600, 400 and 200 γ/ml. Standard discs of Castor oil leaves dipped in different concentrations were offered to each of the third instar larvae. Data clearly showed that the higher the concentration the higher was the percentage of starvation. Considering SC 50 values, Brestan the most active antifeedant was about 1.8, 2.5, 8 and 18 times as much as Duter tetra, Duter, Brestanol and Suzo, respectively. With SC 90 the picture still of the same trend giving 1.3, 3, 4 and 18 times with the above mentioned order. Tested antifeedants were found to decrease the larval weight compared with the control larvae. Zusammenfassung Über die Wirkungen einiger fraβhemmender Stoffe auf Agrotis ypsilon Rott (Lep., Noctuidae) Es wurde die Wirkung der fraβhemmend wirkenden Substanzen Brestan, Brestanol, Duter, Duter tetra und Suzo auf die Raupen von A. ypsilon untersucht. Zu diesem Zwecke wurden Standardscheiben von Rizinusblättern in verschieden konzentrierte (200–10 000 γ/mm) Lösungen dieser Substanzen getaucht. Die Sterblichkeit stieg mit der Konzentration an. Brestan zeigte die beste Wirkung. Es wirkte, bezogen auf die SC50‐Werte, 1,8–2,5,8 und 18 x besser als Duter tetra, Duter, Brestan und Suzo. Bei den SC90‐Werten zeigte sich derselbe Trend. Die Fraßhemmstoffe verminderten das Larvengewicht.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.